Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA1236726
Max Phase: Preclinical
Molecular Formula: C35H38Cl2N6O
Molecular Weight: 629.64
Molecule Type: Small molecule
Associated Items:
ID: ALA1236726
Max Phase: Preclinical
Molecular Formula: C35H38Cl2N6O
Molecular Weight: 629.64
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CN(C)CCCN(C)[C@H]1CCN(C(=O)c2[nH]c3cc(Cl)ccc3c2-c2c(-c3ccccc3)ncn2Cc2ccc(Cl)cc2)C1
Standard InChI: InChI=1S/C35H38Cl2N6O/c1-40(2)17-7-18-41(3)28-16-19-42(22-28)35(44)33-31(29-15-14-27(37)20-30(29)39-33)34-32(25-8-5-4-6-9-25)38-23-43(34)21-24-10-12-26(36)13-11-24/h4-6,8-15,20,23,28,39H,7,16-19,21-22H2,1-3H3/t28-/m0/s1
Standard InChI Key: LWWQYOWAPGRPRH-NDEPHWFRSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 629.64 | Molecular Weight (Monoisotopic): 628.2484 | AlogP: 7.15 | #Rotatable Bonds: 10 |
Polar Surface Area: 60.40 | Molecular Species: BASE | HBA: 5 | HBD: 1 |
#RO5 Violations: 2 | HBA (Lipinski): 7 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 13.30 | CX Basic pKa: 9.53 | CX LogP: 5.97 | CX LogD: 3.71 |
Aromatic Rings: 5 | Heavy Atoms: 44 | QED Weighted: 0.18 | Np Likeness Score: -1.31 |
1. Khoury K, Popowicz GM, Holak TA, Dömling A.. (2011) The p53-MDM2/MDMX axis - A chemotype perspective., 2 (4): [PMID:24466404] [10.1039/c0md00248h] |
2. Guo W, Wisniewski JA, Ji H.. (2014) Hot spot-based design of small-molecule inhibitors for protein-protein interactions., 24 (11): [PMID:24751445] [10.1016/j.bmcl.2014.03.095] |
3. Macchiarulo A, Giacche N, Carotti A, Moretti F, Pellicciari R. (2011) Expanding the horizon of chemotherapeutic targets: From MDM2 to MDMX (MDM4), 2 (6): [10.1039/C0MD00238K] |
4. Liu Y, Wang X, Wang G, Yang Y, Yuan Y, Ouyang L.. (2019) The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy., 176 [PMID:31100649] [10.1016/j.ejmech.2019.05.018] |
5. Zhang S, Lou J, Li Y, Zhou F, Yan Z, Lyu X, Zhao Y.. (2021) Recent Progress and Clinical Development of Inhibitors that Block MDM4/p53 Protein-Protein Interactions., 64 (15.0): [PMID:34286973] [10.1021/acs.jmedchem.1c00940] |
Source(1):